Drug intelligence / Profile preview

Neurotec

Development stage
Unknown
Lead developer
Pars Bioscience
Modality
Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Neurotec is a herbal formulation developed in Iran, primarily investigated by the Iran Rheumatology Center for the management of fibromyalgia syndrome and other chronic inflammatory conditions. It is a standardized combination of three botanical extracts: *Rosa canina* (dog rose), *Tanacetum vulgare* (tansy), and *Urtica dioica* (stinging nettle). The therapeutic effects of Neurotec are attributed to its potent anti-inflammatory and antioxidant properties. Mechanistically, it has been shown to inhibit the production of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), and to reduce oxidative stress markers. Clinical studies, including multi-centre randomized double-blind placebo-controlled trials, have demonstrated its efficacy in reducing pain scores and improving functional outcomes in patients with fibromyalgia and osteoarthritis, often with a favorable safety profile compared to conventional non-steroidal anti-inflammatory drugs (NSAIDs).

Brand names
Neurotec
Other names
Herbal extract of Rosa canina, Tanacetum vulgare, and Urtica dioica
02

Targets

NF-κBIL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Neurotec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurotec.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call